Kiniksa’s Mavrilimumab Fails In Late-Stage COVID-19 Trial, Doubles Back On Arcalyst

 
• By Ayisha Sharma
  
White arrows going in one direction, red arrow going in different direction
Analysts Remain Positive About Kiniksa's Value Driver Arcalyst • Source: Alamy

More from Clinical Trials

More from R&D